News
Market and company headlines
AVTXAll
Loading
07:00-16:00Oct 232 Stories
04:00Oct 232 Stories
This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Analysts downgraded DECK, AVTX, ORI, GL and CASS; price targets were cut for DECK, ORI and GL.
Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $22
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $34 to $22.
01:00-03:00Oct 232 Stories
HC Wainwright & Co. Downgrades Avalo Therapeutics to Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Avalo Therapeutics (NASDAQ:AVTX) from Buy to Neutral.
BTIG Maintains Buy on Avalo Therapeutics, Lowers Price Target to $10
BTIG analyst Julian Harrison maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $58 to $10.
16:00Oct 221 Story
16:00Sep 291 Story
03:00-08:00Sep 232 Stories
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vienna, Austria from September 30-October 3, 2026. EADV Congress 2026 Presentation Details: Late-Breaker Oral Presentation: Title: Efficacy and Safety of A
Avalo Therapeutics To Present Abdakibart Data At EADV Congress 2026
Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker
06:00-17:00Sep 42 Stories
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise
Avalo Therapeutics (AVTX) is now a well-funded, registrational-stage biotech with validated Phase II data for abdakibart in hidradenitis suppurativa (HS).
07:00Sep 31 Story
03:00-10:00Aug 72 Stories
Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48
Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $50 to $48.
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $35 to $30.
